Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of oral LEO 152020 in adults with moderate to severe atopic dermatitis
jRCT2031210485Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of JW1601 in atopic dermatitis (AD) (4 arms), sponsored by LEO Pharma. Primary endpoint: Change in Eczema Area and Severity Index (EASI) from baseline to Week 16. Started Mar 2022; status: completed.
02
Drugs
JW1601
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031210485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210485.